A breakthrough Alzheimer’s drug is about to be evaluated in Europe. It has already been approved in the United States. The drug, called donanemab, could inhibit the disease. A researcher from Den Bosch is optimistic about possible approval in Europe, he tells Brabants Dagblad. If the drug gets the green light, it could mark a turning point in the treatment of Alzheimer’s.
Approval in the U.S.
In the United States, the FDA has already approved donanemab. This means that American patients already have access to the drug. The drug is seen as a potential breakthrough in the fight against Alzheimer’s. It works by reducing the build-up of amyloid proteins in the brain, which is a hallmark of the disease.
European Medicines Agency
Now the focus is on Europe, where the European Medicines Agency (EMA) has the task of reviewing the drug. The approval process is rigorous and extensive. The EMA evaluates not only the effectiveness of donanemab, but also its safety and possible side effects. Researcher Paul Dautzberg of the Brain Research Center in Den Bosch is closely following this process and hopes for a quick and positive assessment.
Optimism and caution
Clinical studies have shown that donanemab can slow the progression of Alzheimer’s, but it is not yet clear how significant these effects are in the long term. There are also questions about which patients will benefit most from the drug. Experts stress that further studies are needed to answer these questions.
The road to approval
The next few months are crucial for the future of donanemab in Europe. The EMA will thoroughly evaluate all the data. If the drug is approved, it will be an important step in the fight against Alzheimer’s.
Related Posts
